Checkpoint Inhibitor Websites
Apogenix ǀ Immuno-oncology therapeutics for the treatment of cancer an
Apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. Our lead drug candidate APG101 has demonstrated a statistically significant efficacy in a controlled phase II trial in recurrent glioblastoma.
3,446,235
$
480.00
Qualigen
Founded in 1996, Qualigen is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases using similar core nanoparticle technology from its flagship FDA-approved FastPack® System, which has been used successfully in diagnostics for over 15 years.
Not Applicable
$
8.95
